Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.
Jänicke
F
F
Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Germany.
Schmitt
M
M
Graeff
H
H
D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local / Q000378:metabolism*; D015849:Plasminogen Inactivators / Q000032:analysis*; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate; D010959:Tissue Plasminogen Activator / Q000032:analysis*; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator